Biomarkers of AD can be described in the ATN (amyloid/tau/neurodegeneration) framework, grouped into those of β amyloid (Aβ) deposition, pathological tau, and neurodegeneration [2]. This evidence concerns the gene MAPT and Alzheimer disease.